FDA says BPA exposure is safe
This article was originally published in The Tan Sheet
FDA concludes the current levels of bisphenol A - a chemical in the container liners of prepared liquid infant formula - that transfer to foods and are absorbed by children are "safe," according to a draft report released Aug. 14. Based on published risk assessments, the agency estimates BPA exposure from food contact materials in infants is less than half the established level for no observed adverse effect. Some scientists, physicians and children's health advocates "expressed outrage" with the agency's conclusion, according to a release from the Center for Health Environment and Justice. Dissenters say FDA relies on two studies funded by the American Chemical Council and ignores dozens of other studies that highlight risks. FDA, however, says that limits in study design and data quality are insufficient to lower the current NOAEL for BPA. Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee and Oversight and Investigations Subcommittee Bart Stupak asked FDA to reconsider BPA safety in infant formulas in April (1"The Tan Sheet" April 21, 2008, In Brief)
You may also be interested in...
FDA will take a second look at bisphenol A in containers, said Commissioner Peggy Hamburg at a House Energy and Commerce Health Subcommittee hearing June 3. Committee Chairman Henry Waxman, D-Calif., asked Hamburg June 2 to reconsider the "possible dangers" of BPA at current exposure levels. He questioned FDA's conclusion under the Bush administration that BPA is safe and urged Hamburg to scrutinize FDA's reliance on industry studies (1"The Tan Sheet" Aug. 25, 2008, In Brief). FDA is reevaluating another Bush era move - its 2006 decision to restrict sales of OTC emergency contraceptive Plan B (2"The Tan Sheet" April 27, 2009, p. 6)
Results of National Toxicology Program research prompt Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Bart Stupak, Oversight and Investigations Subcommittee, to ask FDA to reconsider the safety of the chemical bisphenol A in products intended for use by infants and children. In an April 14 draft brief, the NTP concludes there is "some concern for neural and behavioral effects in fetuses, infants, and children at current human exposures" and "the possibility that bisphenol A may alter human development cannot be dismissed." Stupak says FDA relied on two industry-funded studies to determine the chemical's safety while other authorities "used all available data to reach vastly different conclusions"...
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.